Stock Market

Johnson & Johnson Q2 positive for MedTech – Baird (NYSE:JNJ)

Mario Tama

As soon as Johnson & Johnson (NYSE:JNJ) exceeded expectations with its Q2 2023 results last week, Baird produced a report pointing to brighter days for MedTech, especially due to the accelerating volume of medical procedures and the reduced impact of COVID in China.

With their MedTech division posting double-digit percentage growth, JNJ (JNJ) and rival medical device maker Abbott Laboratories (ABT) posted better-than-expected Q2 results on Thursday, rallying the subsector.

Related Articles

Back to top button